These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 6840764)
1. Incidence of chromosomal aberrations in patients under combined tuberculostatic chemotherapy. Roman IC; Vainer E; Socosan I; Drăghicescu T Hum Genet; 1983; 63(2):191-2. PubMed ID: 6840764 [TBL] [Abstract][Full Text] [Related]
2. Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment. Ekmekçi A; Sayli A Mutat Res; 1995 Apr; 334(2):175-83. PubMed ID: 7885370 [TBL] [Abstract][Full Text] [Related]
3. [The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis]. Knop P; Kindler U; Merholz T Med Welt; 1976 Feb; 27(8):389-90. PubMed ID: 1256308 [No Abstract] [Full Text] [Related]
4. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis]. Zierski M; Bek E Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146 [No Abstract] [Full Text] [Related]
5. Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy. Rac VV; Gupta EV; Thomas IM Mutat Res; 1991 Jan; 259(1):13-9. PubMed ID: 1988820 [TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of pulmonary tuberculosis]. Ludes H Dtsch Med Wochenschr; 1972 Feb; 97(8):289-91. PubMed ID: 5058425 [No Abstract] [Full Text] [Related]
7. [New guidelines for pulmonary tuberculosis therapy]. Steiner A; Medici TC Dtsch Med Wochenschr; 1978 Mar; 103(9):372-5. PubMed ID: 631063 [No Abstract] [Full Text] [Related]
9. [Apoptosis-inducing action of antituberculosis drugs of the main group in vitro]. Vasilyeva OA; Serebryakova VA; Urazova OI; Novitsky VV; Kononova TE; Naslednikova IO Antibiot Khimioter; 2010; 55(11-12):25-9. PubMed ID: 21574422 [TBL] [Abstract][Full Text] [Related]
10. The impact of chemotherapy on the care of patients with tuberculosis. Johnston RF; Wildrick KH Am Rev Respir Dis; 1974 Jun; 109(6):636-64. PubMed ID: 4209115 [No Abstract] [Full Text] [Related]
12. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 1. Comparison of rifampicin-ethambutol-isoniazid with streptomycin-paraminosalcylic acid-isoniazid in the original treatment of pulmonary tuberculosis patients]. Kekkaku; 1971 Oct; 46(10):393-9. PubMed ID: 5147895 [No Abstract] [Full Text] [Related]
13. Genetic effects of drug interaction in tuberculosis patients and their fate. Jaju M; Jaju M; Ahuja YR Teratog Carcinog Mutagen; 1984; 4(3):261-72. PubMed ID: 6205465 [TBL] [Abstract][Full Text] [Related]
14. [Directly observed treatment for tuberculosis in a Buenos Aires City hospital]. González C; Sáenz C; Herrmann E; Jajati M; Kaplan P; Monzón D Medicina (B Aires); 2012; 72(5):371-9. PubMed ID: 23089112 [TBL] [Abstract][Full Text] [Related]
15. [Launois-Bensaude disease; etiopathogenic discussion in a patient treated with tuberculostatic agents]. Warembourg H; Jaillard J; Carre A; Perrard C; Ginestet A; Beuscart F Lille Med; 1975 Feb; 20(2):102-6. PubMed ID: 1142984 [No Abstract] [Full Text] [Related]
16. [Surveillance and complications of antituberculosis chemotherapy]. Duroux P Rev Prat; 1979 Jun; 29(33):2681-90. PubMed ID: 225779 [No Abstract] [Full Text] [Related]
18. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Laszlo A; Rahman M; Raviglione M; Bustreo F Int J Tuberc Lung Dis; 1997 Jun; 1(3):231-8. PubMed ID: 9432369 [TBL] [Abstract][Full Text] [Related]